MLAB vs. SENS, GHRS, OLMA, STOK, IGMS, CALT, CSTL, CVAC, EMBC, and SIBN
Should you be buying Mesa Laboratories stock or one of its competitors? The main competitors of Mesa Laboratories include Senseonics (SENS), GH Research (GHRS), Olema Pharmaceuticals (OLMA), Stoke Therapeutics (STOK), IGM Biosciences (IGMS), Calliditas Therapeutics AB (publ) (CALT), Castle Biosciences (CSTL), CureVac (CVAC), Embecta (EMBC), and SI-BONE (SIBN).
Senseonics (NYSE:SENS) and Mesa Laboratories (NASDAQ:MLAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.
Mesa Laboratories has a net margin of 0.45% compared to Mesa Laboratories' net margin of -270.13%. Senseonics' return on equity of 7.41% beat Mesa Laboratories' return on equity.
Mesa Laboratories received 216 more outperform votes than Senseonics when rated by MarketBeat users. Likewise, 63.82% of users gave Mesa Laboratories an outperform vote while only 25.00% of users gave Senseonics an outperform vote.
Mesa Laboratories has higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.
Senseonics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Mesa Laboratories has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
In the previous week, Senseonics had 5 more articles in the media than Mesa Laboratories. MarketBeat recorded 6 mentions for Senseonics and 1 mentions for Mesa Laboratories. Senseonics' average media sentiment score of 1.46 beat Mesa Laboratories' score of 0.27 indicating that Mesa Laboratories is being referred to more favorably in the news media.
Senseonics currently has a consensus target price of $1.25, suggesting a potential upside of 141.27%. Mesa Laboratories has a consensus target price of $130.00, suggesting a potential upside of 14.67%. Given Mesa Laboratories' higher probable upside, analysts clearly believe Senseonics is more favorable than Mesa Laboratories.
12.4% of Senseonics shares are owned by institutional investors. Comparatively, 90.6% of Mesa Laboratories shares are owned by institutional investors. 3.9% of Senseonics shares are owned by insiders. Comparatively, 5.2% of Mesa Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Mesa Laboratories beats Senseonics on 13 of the 17 factors compared between the two stocks.
Get Mesa Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mesa Laboratories Competitors List
Related Companies and Tools
